Samsung Biologics Raises Manufacturing Contract Value to USD 55.37 Million

• Samsung Biologics on Nov. 2, 2026, revised a drug manufacturing contract's value to KRW 62.82 billion from KRW 32.53 billion.
• The revision reflects a U.S. pharmaceutical customer's request to increase the contract by USD 26.7 million to USD 55.37 million.
• The revised value represents 8.95% of revenue, up from 4.64%.
• The contract runs from Oct. 28, 2020, through Dec. 31, 2030.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung Biologics Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261102800004), on November 02, 2026, and is solely responsible for the information contained therein.